1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Hepatitis C: KOL Insight

  • September 2016
  • Firstword Pharma
Report ID: 3362814

Summary

Table of Contents




As hepatitis C cures multiply, how do experts evaluate the options?
Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus has shifted to cure, and physicians now have more treatment options than ever. But which ones should they use? Key opinion leaders provide their views, as well as give their candid insights on which regimens of the future could change treatment the HCV treatment paradigm again. Download sample pages now
Covering 7 currently marketed drugs and 6 pipeline therapies, this report reveals candid insights about the HCV landscape from 12 KOLs in North America and Europe. You’ll learn which treatments KOLs have confidence in, which ones they question – and which ones they think can challenge the standard of care in the future.
“Even with the new drugs coming into the market, Harvoni's eight-week treatment regimen is a strong argument for Gilead to keep it on the market ... I do not see Epclusa or Zepatier getting into that segment. The only other drug that can be a challenge to Harvoni is [ABT- 493/ABT-530], because they have eight-week results for every population so far."
US KOL







Take a tour of the report now:

The table of contents >
The key questions answered >
The key KOL quotes >
See the 13 therapies covered >
Find out who the 12 EU & US KOLs are >
Review an extract from the report - 1 drug profile >

Sample of brands covered:

Harvoni (sofosbuvir/ledipasvir; Gilead)
Sovaldi (sofosbuvir; Gilead)
Viekira Pak/Viekirax+Exviera (paritaprevir/ ombitasvir/ dasabuvir; AbbVie/Enanta)
Zepatier (elbasvir/grazoprevir; Merck & Co.)
Plus 9 more – download the full list now

Sample of KOLs interviewed

Adrian M. Di Bisceglie. Chief of Hepatology, Division of Gastroenterology and Hepatology, St. Louis University Liver Center, St. Louis, MO.
Eric Lawitz. Medical Director, Texas Liver Institute and Clinical Professor of Medicine, University of Texas Health Science Center, San Antonio, TX.
Geoffrey Dusheiko. Emeritus Professor of Medicine, Royal Free Hospital and University College School of Medicine, London, UK.
Peter Ferenci. Professor of Medicine, Medical University of Vienna, Vienna, Austria.
Plus 8 more – download the full list now

Top Takeaways

KOLs see room for improvement in streamlining the route to HCV cure. Do KOLs believe there is a future without ribavirin? What else is on their wish lists?
FDCs have challenged the utility of single-agent therapies. Do experts believe that monotherapies, including Sovaldi, Olysio and Daklinza, have a future role in treatment?
KOLs agree that governments’ good intentions to increase rates of HCV screening have had limited success. Beyond identifying more patients, where do KOLs see unmet needs in HCV?
Experts concur that existing drugs can successfully treat most patients with the common HCV genotypes. With little room for improving SVR rates, where do KOLs see the biggest opportunities for new entrants addressing these genotypes?
Pan-genotypic regimens stand to simplify the HCV treatment paradigm. Other than simplicity, what do KOLs expect from other pan-genotypic therapies in development?
Cost is the main factor determining the market availability of HCV drugs in many countries. How do KOLs feel about this?
Experts are intrigued by pipeline drugs targeting new pathways. Regulus Therapeutics’ RG-101 and Biotron’s BIT225 look interesting, but how do KOLs view their safety profile and market potential?


Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.


Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.

You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Hepatitis C disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridae virus family and is a communicable disease spread primarily through direct ...

Market Access Impact (EU5) [HIV]

  • $ 5440
  • Industry report
  • April 2017
  • by Firstword Pharma

HIV drug market barriers: A help or a hindrance? Today’s tightly packed European HIV drug landscape is the culmination of numerous innovative developments over the last three decades. New market entrants ...

Market Access Impact (US) [HIV]

  • $ 5440
  • Industry report
  • April 2017
  • by Firstword Pharma

Are US market barriers helping or hindering your HIV brand? Today’s tightly packed US HIV drug landscape is the culmination of numerous innovative developments over the last three decades. New market ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.